[Influence of the sociodemographic and clinical profile of dyslipidaemic patients on their compliance with dietary advice combined with cholesterol-lowering drug treatment (nutrivast survey)].
OBJECTIVE
To describe the compliance of dyslipidaemic patients with health and dietary advice combined with cholesterol-lowering drug treatment according to their sociodemographic and clinical profile.


METHODS
French cross-sectional epidemiological survey conducted in dyslipidaemic patients requiring introduction of lipid-lowering treatment, based on a combination of clinical description of the patient by the doctor and a strictly anonymous self-administered questionnaire returned directly to the data analysis centre, allowing patients to freely express themselves about their compliance with health and dietary advice.


RESULTS
7902 patients with a mean age of 58 +/- 12 years, predominantly males (62.3%) were included in the study. The study of eating behaviour showed that 24.9% of patients presented poor compliance with dietary advice. Compliance was better in women, in patients over the age of 60, in people living at home or retired than in working or unemployed people, in urban dwellers than in rural dwellers, in patients eating lunch and dinner at home rather than in a restaurant. Patients with the greatest number of cardiovascular risk factors presented the poorest compliance with dietary advice, patients in a secondary prevention setting do not present better compliance than patients in a primary prevention setting, and those whose previous treatment was insufficient do not comply with dietary advice better than those in a treatment initiation setting.


CONCLUSIONS
This study shows that the fundamental value of diet appears to be poorly understood by patients, who perceive it exclusively as a way of decreasing their cholesterol level and not as a measure able to improve their global cardiovascular prognosis. This probably explains why so many patients no longer see the point of diet once they have started lipid-lowering treatment.
Allaert
F A
FA
Département d'evaluation CHRU du Bocage, 21000 Dijon, France. cenbiotech@ipac.fr
D000368:Aged; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003430:Cross-Sectional Studies; D018752:Diet, Fat-Restricted; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance; D012959:Socioeconomic Factors; D011795:Surveys and Questionnaires
D000924:Anticholesteremic Agents